This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

XTL Biopharmaceuticals Successfully Completes A Capital Raise In Israel Of Approximately $3.5 Million Led By Institutional Investors

HERZELIYA, Israel, March 19, 2012 /PRNewswire/ --

 $1.1 million was raised by way of exercise of tradable warrants at NIS 1.05 per share  ( $0.56   per ADR).

$2.4 million was raised in a lock-up private placement at a share price of NIS 0.79 per share  ( $0.42   per ADR).

The raise will enable acceleration of the clinical development programs of the Company.

XTL Biopharmaceuticals (TASE: XTL, OTC: XTLBY) announced yesterday, March 18, 2012, it successfully completed a private placement of securities with foreign as well as Israeli institutional and private investors for a total of $2.4 million ( NIS 9.1 million). The placement will have a 6-month lock-up period. Furthermore, the Company raised an additional approximate $1.1 million ( NIS 4.2 million) by way of exercise of tradable warrants (series 2) at NIS 1.05 per share ( $0.56 per ADR).

The private placement together with the warrants' exercise totalled to approximately $3.5 million (approximately NIS 13.3 million). Menora Mivtahim Underwriting and Management Ltd. acted as an advisor for the private placement.

 "We are happy to announce the completion of the raising, led by key institutional investors" mentioned Ronen Twito, XTL's Chief Financial Officer, and added "the completion of the raising and its character demonstrate the investors' belief in the Company, and will enable the Company to mark the US capital markets as a target in the near future."

David Grossman, XTL's Chief Executive Officer said "We would like to thank the investors and our shareholders for their investment and support in the Company. The raising will enable us to accelerate our development programs and expand our drug development pipeline."

About XTL Biopharmaceuticals, Ltd.

XTL Biopharmaceuticals, Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. The Company is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs